Search

How Can We Help You?

Video

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Solid Tumors

Select Clinical Trial

Protocol Number: NCI Protocol # 10323

Protocol Title: Cancer Moonshot Biobank Research Protocol

Eligibility: Men or women age 18 and older undergoing standard of care therapy for stage IV colorectal, stage III/IV lung, metastatic castration-resistant prostate, stage IV gastroesophageal, stage III/IV melanoma, or treatment refractory multiple myeloma cancers, and willing to provide longitudinal biospecimens.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: BioAtla 3021-001

Protocol Title: A phase 1 or 2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors.

Eligibility: Men and women age 18 and older with histologically or cytologically confirmed ROR2 positive locally advanced unresectable or metastatic NSCLC or melanoma after disease progression following PD-1/L-1, EGFR inhibitor, or ALK inhibitor therapy.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Chair Exercise

Protocol Title: A randomized pragmatic chair-based home exercise intervention for mitigating cancer-related fatigue in older adults undergoing chemotherapy for advanced disease

Eligibility: Men and women aged 70 and older with advanced cancer, reporting moderate to severe fatigue, and less than 60 minutes of physical activity per week.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: S2013

Protocol Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligibility: Men or women age 18 and older, planning to receive immunotherapy only for a solid tumor malignancy.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Mirati Krystal MRTX849

Protocol Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Eligibility: Men or women, ages 18 and older, diagnosed with advanced cancer, which has a KRAS G12C mutation. 

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: EAY131/MATCH

Protocol Title: Molecular Analysis for Therapy Choice (MATCH)

Eligibility: Men or women, ages 18 and older whose cancer has not responded to conventional treatment or whose cancer does not have a known effective treatment. Patients/treating physician must have received notification of actionable mutation of interest(aMOI) following genetic testing of tumor at an accepted outside laboratory such as Foundation One, Caris, etc.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Seattle Genetics SGNLVA-005; NCT04032704

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Eligibility: Men and women age 18 and older diagnosed with metastatic lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, gastric, gastroesophageal junction (GEJ) adenocarcinoma, Castrate Resistant Prostate cancer, or Melanoma who have progressed following their first line of therapy.

Contact Information: (910) 715-2200

Specialties
Clara McLean House
Make a Donation
News & Events